Results 181 to 190 of about 4,640 (210)

A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers

Gynecologic Oncology, 2021
William P Tew, Roisin E. O'Cearbhaill, Vicky Makker   +2 more
exaly  

Selinexor for Refractory Multiple Myeloma

New England Journal of Medicine, 2019
Kenar D, Jhaveri, Rimda, Wanchoo
openaire   +2 more sources

Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system

Antiviral Research, 2021
Yosef Landesman, Jackelyn Murray, Ralph A. Tripp   +2 more
exaly  

Decitabine/selinexor/tucidinostat

Reactions Weekly, 2023
openaire   +1 more source

Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice

Medical Oncology
Piotr Remiszewski, Wiktor Gaik, Aleksandra Skora, Julia Wąż, Kinga Filipek, Agata Pisklak, M. Dudzisz-Śledź, Piotr Rutkowski, A. Czarnecka   +8 more
semanticscholar   +1 more source

A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia

Leukemia and Lymphoma, 2021
Michael Heuser, Hongtao Liu, Pau Montesinos   +2 more
exaly  

Selinexor

Reactions Weekly
openaire   +2 more sources

Bortezomib/dexamethasone/selinexor

Reactions Weekly, 2022
openaire   +1 more source

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1

Biomedicine and Pharmacotherapy, 2023
Yosef Landesman, Dirk Daelemans, Bert Kwanten   +2 more
exaly  

FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models

Biochemical Pharmacology, 2018
Laura Gatti, Lucia Minoli, Michelandrea De Cesare   +2 more
exaly